Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab in New-onset Type 1 Diabetes
NCT04589325Phase 2Active, not recruiting
- Sponsor
- University of Gothenburg
- Start
- Nov 2022
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ixekizumab in type 1 diabetes mellitus (T1D), sponsored by University of Gothenburg. Started Nov 2022; status: active, not recruiting.
02
Drugs
ixekizumab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04589325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04589325.